Plain-English translation of NCT02896335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a medication that slows cancer cell growth—alone or combined with (a drug that helps your immune system fight cancer) can treat cancer that has spread to the brain. Researchers want to see if these medications are safe and effective for people whose brain tumors are getting worse despite previous treatments.
Brain metastases are difficult to treat and often come back or keep growing even after surgery or radiation. This medication has not yet been approved specifically for brain cancer spread, but early signs suggest it might help. This trial will test whether it works and is safe for this serious condition.
You likely qualify if…
You likely don't qualify if…
You will take as an oral pill once daily for 21 days in each 28-day cycle. If you are in Cohort 2, you will also receive as an intravenous infusion once every 21 days. You will have regular study visits for blood tests, imaging scans, and check-ups to monitor how you are responding and track any side effects. Treatment continues as long as the medication is helping and you are not experiencing severe side effects. After treatment ends, you will be followed for up to 2 years.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States